


































![]()
Q1: 2026-05-14 Earnings Summary
EPS of -$1.24 beats by $0.20
|
Revenue of
$35.07M
(16.83% Y/Y)
beats by $3.67M
Karyopharm Therapeutics Inc. (KPTI) Q1 2026 Earnings Call May 14, 2026 8:00 AM EDT
Company Participants
Brendan Strong - Senior Vice President of Investor Relations
Richard Paulson - President, CEO & Director
Reshma Rangwala - Executive VP, Chief Medical Officer & Head of Research
Sohanya Cheng - Executive VP, Chief Commercial Officer & Head of Business Development
Lori Macomber - EVP, CFO & Treasurer
Conference Call Participants
Brian Abrahams - RBC Capital Markets, Research Division
Edward Tenthoff - Piper Sandler & Co., Research Division
Ioannis Souroutzidis - Cantor Fitzgerald & Co., Research Division
Maurice Raycroft - Jefferies LLC, Research Division
Jonathan Chang - Leerink Partners LLC, Research Division
Michael King - Rodman & Renshaw Research
Presentation
Operator
Good morning, everybody. My name is Kelsey, and I will be your conference operator for today. At this time, I would like to welcome everyone to the Karyopharm Therapeutics First Quarter 2026 Financial Results Conference Call. [Operator Instructions] Please be advised that this call is being recorded at the company's request.
I would now like to turn the call over to Mr. Brendan Strong, Senior Vice President, Investor Relations. Please go ahead.
Brendan Strong
Senior Vice President of Investor Relations
Good morning, and thank you all for joining us on today's conference call to discuss Karyopharm's first quarter 2026 financial results and recent company progress. We issued a press release this morning detailing our financial results for the first quarter of 2026. This release, along with a slide presentation that we will reference during our call today, are available on our website.
For today's call, as seen on Slide 2, I'm joined by Richard, Reshma, Sohanya and Lori, who will provide an update on the results for the first quarter, highlight the importance of the results from our Phase III SENTRY trial in myelofibrosis and provide an update on our endometrial cancer program and related commercial
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。